---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-050029"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:34:21.682550+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Scott Brun, M.D., appointed to Jasper Board as R&D Committee Chair; Klein resigns

## Summary
- Scott Brun, M.D., appointed as Class I director effective June 20, 2023; chairs R&D Committee, serves on Compensation Committee.
- Dr. Brun has over 20 years pharma R&D leadership, including AbbVie, Abbott, and Horizon Therapeutics.
- Lawrence Klein, Ph.D., resigned effective June 20, 2023, due to his recent appointment as a Partner at Versant Ventures.
- Vishal Kapoor appointed to Audit and Compensation Committees.
- Dr. Brun receives initial option grant of 94,000 shares vesting over 4 years under Director Compensation Policy.

## SEC filing metadata
- accession: 0001213900-23-050029
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/0001213900-23-050029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/ea180573-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-050029
- JSON: https://secwatch.observer/filing/0001213900-23-050029.json
- Plain text: https://secwatch.observer/filing/0001213900-23-050029.txt

## Key facts
- Executive change
  Scott Brun was appointed as Class I Director at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: Effective June 20, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Scott Brun, M.D., as a Class I director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/0001213900-23-050029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.